FindTrial
Sign In

A Study To Compare The Anti-Anginal Efficacy Or Effectiveness Between Two Drugs, Ranolazine And Nicorandil In Ischemic Heart Disease Patients Attending A Tertiary Care Hospital In Kolkata.

An Observational Study To Compare The Anti-Anginal Efficacy Of Ranolazine And Nicorandil In Ischemic Heart Disease Patients Attending A Tertiary Care Hospital In Kolkata.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/10/028644
Enrollment
100
Registered
2020-10-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I259- Chronic ischemic heart disease, unspecified

Interventions

None listed

Sponsors

IPGMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Documented stable ischemic heart disease written informed consent from patient or legally acceptable representative

Exclusion criteria

Exclusion criteria: patients having unstable critical conditions like recent onset Acute Coronary Syndrome, Acute Heart Failure (reduced ejection fraction), associated cardiomyopathy, life threatening comorbidities, any types of anemia or part of any other trial or expressing inability for follow up for 6 months.

Design outcomes

Primary

MeasureTime frame
Seattle Angina Questionnaire 7 score will be calculated at baseline, 1.5 months, 3 months and 6 months and will be compared between them to asses the efficacy of the antianginal drugs.Timepoint: from june 2019 to november 2020—

Secondary

MeasureTime frame
HbA1C lowering effects provided by Ranolazine if any and any adverese effects by the study drugs nicorandil and ranolazine at 6 months of the studyTimepoint: from june 2019 to november 2020—

Countries

India

Contacts

Public ContactDr Arup Ratan Mallick

IPGME&R and SSKM Hospital

drgairiksengupta@yahoo.co.in9874621539

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026